Patricia Sheean

Dr. Patricia Sheean


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2014 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
CBCarol A. Braunschweig
Carol A. Braunschweig
PSPatricia Sheean
Patricia Sheean
SPSarah J. Peterson
Sarah J. Peterson
SPSandra Gomez Perez
Sandra Gomez Perez
SFSally A Freels
Sally A Freels
GFGiamila Fantuzzi
Giamila Fantuzzi

19 June 2019 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
PDF file
PSPatricia Sheean
Patricia Sheean
Maria Cristina GonzalezMaria Cristina Gonzalez
Maria Cristina Gonzalez
CPCarla M. Prado
Carla M. Prado
LMLiam McKeever
Liam McKeever
AHAmber M. Hall
Amber M. Hall
CBCarol A. Braunschweig
Carol A. Braunschweig
On behalf of the American Society for Parenteral and Enteral Nutrition (ASPEN), a systematic review was conducted to evaluate the best available evidence regarding the validity of relevant body composition methods (eg, dual energy X‐ray absorptiometry [DXA], ultrasound [US], and bioelectrical impedance analysis [BIA]) in clinical populations. The guidelines targeted adults >18 years of age with a potentially inflammatory condition or pathological end point associated with a specific disease or clinical condition. In total, 7375 studies were retrieved, and 15 DXA, 7 US, and 23 BIA studies provided applicable data. The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses was used to assess the diagnostic accuracy of the test method against a “gold standard” reference. The Grading of Recommendations, Assessment, Development and Evaluation criteria were used to separate the evaluation of the body of evidence from the recommendations. Based on a limited number of studies and expert opinion, DXA is recommended for the assessment of fat mass in patients with a variety of disease states; however, the validity of DXA for lean mass assessment in any clinical population remains unknown. No recommendations can be made at this time to support the use of US or BIA in the clinical setting, as data to support its validity in any specific patient population are limited in scope or by the proprietary nature of manufacture‐specific BIA regression models to procure body composition data, respectively. Directions for future research are provided. These clinical guidelines were approved by the ASPEN Board of Directors.


22 May 2022 in Journal of Human Nutrition and Dietetics
Verified
Journal Article
Open access
KFKy Ford
Ky Ford
EHElizabeth Huggins
Elizabeth Huggins
PSPatricia Sheean
Patricia Sheean
Background: Gender‐affirming hormone therapy (GAHT) is prescribed to produce secondary sex characteristics aligning external anatomy with gender identity to mitigate gender dysphoria. Transgender women are generally treated with oestrogens and anti‐androgens, whereas transgender men are treated with testosterone. The objective of this narrative review was to characterise the influence of GAHT on body composition and bone health in the transgender population to help address weight concerns and chronic disease risk.Methods: Studies were extracted from PubMed and Scopus and limited to only those utilising imaging technologies for precise adipose tissue, lean mass, and bone mineral density (BMD) quantification.Results: Although methodologies differed across the 20 investigations that qualified for inclusion, clear relationships emerged. Specifically, among transgender women, most studies supported associations between oestrogen therapy and decreases in lean mass and increases in both, fat mass and body mass index (BMI). Within transgender men, all studies reported associations between testosterone therapy and increases in lean mass, and although not as consistent, increases in BMI and decreases in fat mass. No consistent changes in BMD noted for either group.Conclusions: Additional research is needed to appropriately assess and evaluate the implications of these body composition changes over time (beyond 1 year) in larger, more diverse groups across all BMI categories. Future studies should also seek to evaluate nutrient intake, energy expenditure and other important lifestyle habits to diminish health disparities within this vulnerable population. Policies are needed to help integrate registered dietitians into the routine care of transgender individuals.

24 July 2015 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
BDBethany Doerfler
Bethany Doerfler
TATara S. Allen
Tara S. Allen
CSCourtney Southwood
Courtney Southwood
DBDarren Brenner
Darren Brenner
IHIkuo Hirano
Ikuo Hirano
PSPatricia Sheean
Patricia Sheean

3 March 2022 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
SPSue Penckofer
Sue Penckofer
MRMonique Ridosh
Monique Ridosh
WAWilliam Adams
William Adams
MGMeghan Grzesiak
Meghan Grzesiak
JWJennifer Woo
Jennifer Woo
Angelos HalarisAngelos Halaris
Angelos Halaris
Aim. To determine the efficacy and safety of vitamin D3 supplementation in reducing depressive symptoms in women with type 2 diabetes (T2D), depression, and low vitamin D. Methods. In this double-blind randomized active comparator-controlled trial, women with significant depressive symptoms as assessed by the Center for Epidemiologic Studies Depression (CES-D) scale received weekly oral vitamin D3 supplementation (50,000 IU) or an active comparator (5,000 IU) for 6 months. Assessments of vitamin D, 25-hydroxyvitamin D [25 (OH) D], and depression were measured at baseline, 3 months, and 6 months. Results. A total of 129 women were randomized, from which 119 completed the study (57 in lower dose and 62 in higher dose). Participants had an average 25 (OH) D and HbA1c of 20.8 ng/mL and 7.8%, respectively, at baseline. They were diverse (48% Black) and had a mean age of 50 and T2D for about 8 years. Upon completion of vitamin D3 supplementation, serum 25 (OH) D levels increased with 50,000 IU (+34 ng/mL) and 5,000 IU (+10 ng/mL). There was no difference in CES-D scores by treatment dose. Overall, depressive symptoms significantly improved over time with an average CES-D decline of 12.98 points (95% CI: −15.04 to −10.93; ). Among women with moderate baseline depressive symptoms, those receiving the lower dose had nominally lower depression scores at follow-up than those in the higher dose cohort. Among women with severe baseline depressive symptoms, the improvement in follow-up depression scores was the same regardless of dose. Conclusions. There was no difference in the dosing effect of vitamin D3 supplementation for the treatment of depressive symptoms in women with T2D who present with significant symptoms and low vitamin D. Regardless of the dose, participants’ mood improved over time. Further study of vitamin D to target depressive symptoms in comorbid populations is needed.